Pro-Dex, Inc. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2017; comparisons are with the year ended June 30, 2016. The filing is a fiscal 2017 annual report, notwithstanding the request metadata’s “2016 Q4” label.
Business context
Pro-Dex designs and manufactures powered surgical and dental instruments, principally for orthopedic, spine, and cranio-maxillofacial markets. Medical device products and services generated 85% of FY2017 sales. The company sold its Oregon Micro Systems (OMS) division in January 2017 and reported it as a discontinued operation. It also ended placement services and disbanded its Engineering Services Division in April 2017, while retaining some engineering, quality, and regulatory consulting work.
Financial results and liquidity
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net sales | $21.943 million | $19.189 million |
| Gross profit / margin | $7.186 million / 33% | $4.918 million / 26% |
| Operating income | $2.734 million | $0.807 million |
| Income from continuing operations | $4.841 million | $1.103 million |
| Net income | $5.084 million | $0.822 million |
| Diluted EPS | $1.25 | $0.20 |
| Cash from operating activities | $3.235 million | $0.466 million |
FY2017 net income included a $2.089 million income tax benefit, driven principally by release of approximately $3.3 million of valuation allowance on deferred tax assets. The benefit is a significant, non-recurring contributor to reported earnings; management expected FY2018 effective tax rates to be closer to statutory rates.
At June 30, 2017, cash and cash equivalents were $4.205 million, working capital was $9.341 million, and total liabilities were $2.641 million. Notes and capital lease obligations totaled approximately $119,000. A $500,000 secured revolving facility was undrawn. Operating cash flow rose from the prior year; the cash flow reconciliation reflects a $2.048 million deferred tax benefit adjustment.
Material changes versus FY2016
- Sales rose 14%, mainly from a $4.3 million increase in medical device sales, including higher volumes of a surgical handpiece for the largest customer.
- Gross margin improved from 26% to 33%, which management attributed largely to bringing previously outsourced manufacturing in-house and lower relative cost growth.
- Operating income increased to $2.734 million. General and administrative expense rose $647,000, primarily from bonus accruals and higher legal and professional fees.
- Backlog declined to $8.7 million from $11.3 million.
- Cash increased to $4.205 million. The company invested $663,000 in marketable securities, made $606,000 of capital expenditures, and advanced $450,000 to Monogram Orthopaedics.
- OMS contributed $243,000 of discontinued-operation income in FY2017, including a gain on sale; FY2016 discontinued operations recorded a $281,000 loss.
Outlook, risks, and unusual items
- Management said available cash, receivables, and expected operating cash flows should fund the business for at least 12 months. It may use the bank revolver or issue shares through its ATM facility for working capital or investment needs.
- One customer represented 50% of FY2017 sales, and the top 20 represented 94%. The largest customer had purchase commitments through calendar 2018. Separately, the former leading customer’s sales fell to $1.5 million from $3.6 million as it began manufacturing a product itself; Pro-Dex expected further declines.
- The $450,000 Monogram secured convertible note bears 4% interest and matures in April 2019; a further $350,000 advance was conditional on milestones. Management described the investment as long-term, with meaningful revenue potentially years away, if at all. Monogram needs additional financing to advance its regulatory path.
- Pro-Dex disclosed ongoing litigation related to the Riverside foreclosure. Damages were unspecified; the company said it believed it had a reasonable likelihood of prevailing but gave no assurance. A separate former-employee commission claim was settled for $30,000.
- The Irvine lease was due to expire in April 2018; renewal negotiations were ongoing. Subsequent to year-end, the company sold 227,319 shares through its ATM for approximately $1.5 million net proceeds through September 7, 2017.
- Key risks include customer concentration and order variability, competition and product acceptance, warranty estimates on newer products, supplier dependence, regulatory compliance, and the ability to retain key personnel. The company reported effective disclosure controls and internal control over financial reporting; the auditor did not attest to internal controls.
Most important facts for investors to verify
- Whether the 50%-of-sales customer sustains orders and whether its purchase commitments extend beyond calendar 2018; distinguish it from the former major customer whose sales are declining.
- Whether FY2017 margin improvement and operating cash generation persist, given the lower backlog and customer-order variability.
- The recoverability of deferred tax assets and the resulting normalized tax rate after the FY2017 valuation-allowance release.
- Monogram’s milestone completion, financing and regulatory progress, and whether the additional $350,000 advance was made.
- Developments in Riverside litigation, the Irvine lease renewal, and any further ATM share issuance and dilution.